Senti Bio Spins Off Lead Cancer Asset SENTI-202 to Celadon, Retains Regulator Dial Platform
SNTI sits 24% above its 52-week low of $0.77 on light trading volume (0.3× avg).
Summary
Senti Bio is spinning off its lead clinical asset, SENTI-202, to a Celadon-controlled private company. Stockholders receive contingent value rights (CVRs) worth up to $60M in milestone payments over seven years, tied to BLA filing, FDA approval, and $200M in cumulative sales. The move follows months of dilutive financing from Celadon, which now controls the company. Senti Bio will retain its Regulator Dial platform and early-stage programs in Rett Syndrome and solid tumor TILs, seeking additional financing post-close. The transaction requires stockholder approval and aims to unlock value from SENTI-202 while letting the remaining public entity focus on next-generation controllable genetic medicines.
At the time of this announcement, SNTI was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.1M. The 52-week trading range was $0.77 to $2.88. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.